Logo image of MDWD

MEDIWOUND LTD (MDWD) Stock Fundamental Analysis

NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD

20.87  +0.36 (+1.76%)

After market: 20.9 +0.03 (+0.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MDWD. MDWD was compared to 198 industry peers in the Pharmaceuticals industry. MDWD may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MDWD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDWD has reported negative net income.
MDWD had a negative operating cash flow in the past year.
In the past 5 years MDWD always reported negative net income.
MDWD had a negative operating cash flow in each of the past 5 years.
MDWD Yearly Net Income VS EBIT VS OCF VS FCFMDWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -41.12%, MDWD perfoms like the industry average, outperforming 44.95% of the companies in the same industry.
The Return On Equity of MDWD (-97.02%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.12%
ROE -97.02%
ROIC N/A
ROA(3y)-30.14%
ROA(5y)-37.73%
ROE(3y)-99.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDWD Yearly ROA, ROE, ROICMDWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

MDWD has a Gross Margin (13.03%) which is in line with its industry peers.
In the last couple of years the Gross Margin of MDWD has declined.
The Profit Margin and Operating Margin are not available for MDWD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.33%
GM growth 5Y-26.97%
MDWD Yearly Profit, Operating, Gross MarginsMDWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

MDWD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDWD has more shares outstanding
The number of shares outstanding for MDWD has been increased compared to 5 years ago.
The debt/assets ratio for MDWD has been reduced compared to a year ago.
MDWD Yearly Shares OutstandingMDWD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDWD Yearly Total Debt VS Total AssetsMDWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MDWD has an Altman-Z score of -0.89. This is a bad value and indicates that MDWD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MDWD (-0.89) is comparable to the rest of the industry.
MDWD has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, MDWD is in line with its industry, outperforming 46.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC8.87%
MDWD Yearly LT Debt VS Equity VS FCFMDWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

MDWD has a Current Ratio of 1.97. This is a normal value and indicates that MDWD is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.97, MDWD perfoms like the industry average, outperforming 41.41% of the companies in the same industry.
MDWD has a Quick Ratio of 1.86. This is a normal value and indicates that MDWD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.86, MDWD is in line with its industry, outperforming 44.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.86
MDWD Yearly Current Assets VS Current LiabilitesMDWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MDWD have decreased strongly by -298.70% in the last year.
MDWD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.21%.
The Revenue has been decreasing by -8.65% on average over the past years.
EPS 1Y (TTM)-298.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.47%
Revenue 1Y (TTM)8.21%
Revenue growth 3Y-5.23%
Revenue growth 5Y-8.65%
Sales Q2Q%9.4%

3.2 Future

Based on estimates for the next years, MDWD will show a very strong growth in Earnings Per Share. The EPS will grow by 22.99% on average per year.
Based on estimates for the next years, MDWD will show a very strong growth in Revenue. The Revenue will grow by 46.19% on average per year.
EPS Next Y5.31%
EPS Next 2Y9.91%
EPS Next 3Y12.56%
EPS Next 5Y22.99%
Revenue Next Year20.91%
Revenue Next 2Y23.66%
Revenue Next 3Y26.07%
Revenue Next 5Y46.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDWD Yearly Revenue VS EstimatesMDWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
MDWD Yearly EPS VS EstimatesMDWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDWD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDWD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDWD Price Earnings VS Forward Price EarningsMDWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDWD Per share dataMDWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

MDWD's earnings are expected to grow with 12.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.91%
EPS Next 3Y12.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDWD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIWOUND LTD

NASDAQ:MDWD (5/20/2025, 8:15:17 PM)

After market: 20.9 +0.03 (+0.14%)

20.87

+0.36 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/bmo
Earnings (Next)05-21 2025-05-21/bmo
Inst Owners39.54%
Inst Owner Change-3.2%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap225.60M
Analysts83.64
Price Target30.6 (46.62%)
Short Float %12.77%
Short Ratio14.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.41%
Min EPS beat(2)-116.72%
Max EPS beat(2)41.9%
EPS beat(4)1
Avg EPS beat(4)-71.67%
Min EPS beat(4)-153.13%
Max EPS beat(4)41.9%
EPS beat(8)4
Avg EPS beat(8)-17.36%
EPS beat(12)4
Avg EPS beat(12)-24.42%
EPS beat(16)7
Avg EPS beat(16)-21.39%
Revenue beat(2)0
Avg Revenue beat(2)-14.65%
Min Revenue beat(2)-28.91%
Max Revenue beat(2)-0.39%
Revenue beat(4)1
Avg Revenue beat(4)-6.73%
Min Revenue beat(4)-28.91%
Max Revenue beat(4)4.26%
Revenue beat(8)2
Avg Revenue beat(8)-5.71%
Revenue beat(12)5
Avg Revenue beat(12)3.17%
Revenue beat(16)8
Avg Revenue beat(16)3.55%
PT rev (1m)-3.23%
PT rev (3m)3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.71%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)-23.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.16
P/FCF N/A
P/OCF N/A
P/B 7.24
P/tB 7.26
EV/EBITDA N/A
EPS(TTM)-3.07
EYN/A
EPS(NY)-2.91
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS1.87
BVpS2.88
TBVpS2.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.12%
ROE -97.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.03%
FCFM N/A
ROA(3y)-30.14%
ROA(5y)-37.73%
ROE(3y)-99.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.33%
GM growth 5Y-26.97%
F-Score2
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 422.99%
Cap/Sales 31.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.86
Altman-Z -0.89
F-Score2
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)321.06%
Cap/Depr(5y)217.42%
Cap/Sales(3y)22.58%
Cap/Sales(5y)14.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-298.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.47%
EPS Next Y5.31%
EPS Next 2Y9.91%
EPS Next 3Y12.56%
EPS Next 5Y22.99%
Revenue 1Y (TTM)8.21%
Revenue growth 3Y-5.23%
Revenue growth 5Y-8.65%
Sales Q2Q%9.4%
Revenue Next Year20.91%
Revenue Next 2Y23.66%
Revenue Next 3Y26.07%
Revenue Next 5Y46.19%
EBIT growth 1Y-26.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.19%
OCF growth 3YN/A
OCF growth 5YN/A